Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.38
-0.21 (-0.85%)
At close: Jun 12, 2026, 4:00 PM EDT
23.91
-0.47 (-1.91%)
After-hours: Jun 12, 2026, 7:40 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
1.17M LKR
Profits / Employee
-6.71K LKR
Market Cap
3.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Beam Therapeutics | 522 |
| Denali Therapeutics | 507 |
| Dyne Therapeutics | 263 |
| Alumis | 227 |
| Structure Therapeutics | 220 |
| Relay Therapeutics | 193 |
ARQT News
- 5 days ago - Arcutis Biotherapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Arcutis Biotherapeutics Transcript: AGM 2026 - Transcripts
- 11 days ago - New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - GlobeNewsWire
- 19 days ago - Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley - TheFly
- 5 weeks ago - Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c) - TheFly
- 5 weeks ago - Arcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M - TheFly